Grant: Project Grant
University of Toronto
$100,000.00
Investigating a novel phosphoinositide-lysosomal signalling axis for pancreatic cancer therapy
EF 2022-23
Résumé
Despite improvements in our understanding of pancreatic cancer biology in the last two decades, this disease is still among the most devastating of all cancers. It is clear that researchers still have much to learn about what triggers pancreatic cancers to develop and why the disease is so aggressive. Our research team has discovered that when a protein enzyme called INPP4B is at high levels in pancreatic cancer cells, patients are more likely to have shorter survival times. We have also learned that INPP4B can increase the number and function of lysosomes in pancreatic cancer. Recent studies show that overactive lysosomes can make cancer cells more agressive and resistant to chemotherapy. When we experimentally increase INPP4B levels in pancreatic cancer cells they grow faster, move faster and they do not die when treated with chemotherapy. These features highlight that INPP4B may make pancreatic cancer more aggressive. Our studies aim to answer the following question: Can direct blockade of INPP4B protein, or indirect blockade through its functions (e.g. lysosome activation) make pancreatic cells grow slower, move slower and die when treated with chemotherapy. We believe that our studies of INPP4B can teach us more about pancreatic cancer cells, and perhaps how to kill them more effectively.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
477270
Name
Salmena Leonardo L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics 2
Projecttitle
Investigating a novel phosphoinositide-lysosomal signalling axis for pancreatic cancer therapy
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Chemoresistance; Inpp4b; Lysosome; Metastasis; Pancreas; Phosphoinositide Signalling
Abstract
Despite improvements in our understanding of pancreatic cancer biology in the last two decades, this disease is still among the most devastating of all cancers. It is clear that researchers still have much to learn about what triggers pancreatic cancers to develop and why the disease is so aggressive. Our research team has discovered that when a protein enzyme called INPP4B is at high levels in pancreatic cancer cells, patients are more likely to have shorter survival times. We have also learned that INPP4B can increase the number and function of lysosomes in pancreatic cancer. Recent studies show that overactive lysosomes can make cancer cells more agressive and resistant to chemotherapy. When we experimentally increase INPP4B levels in pancreatic cancer cells they grow faster, move faster and they do not die when treated with chemotherapy. These features highlight that INPP4B may make pancreatic cancer more aggressive. Our studies aim to answer the following question: Can direct blockade of INPP4B protein, or indirect blockade through its functions (e.g. lysosome activation) make pancreatic cells grow slower, move slower and die when treated with chemotherapy. We believe that our studies of INPP4B can teach us more about pancreatic cancer cells, and perhaps how to kill them more effectively.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Salmena, Leonardo L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~